- Home
- KCHV vs RIGL Comparison
KCHV vs RIGL Comparison
Compare KCHV & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KCHV
- RIGL
- Stock Information
- Founded
- KCHV 2025
- RIGL 1996
- Country
- KCHV United States
- RIGL United States
- Employees
- KCHV N/A
- RIGL N/A
- Industry
- KCHV
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- KCHV
- RIGL Health Care
- Exchange
- KCHV NYSE
- RIGL Nasdaq
- Market Cap
- KCHV 343.0M
- RIGL 335.5M
- IPO Year
- KCHV 2025
- RIGL 2000
- Fundamental
- Price
- KCHV $10.03
- RIGL $21.91
- Analyst Decision
- KCHV
- RIGL Buy
- Analyst Count
- KCHV 0
- RIGL 5
- Target Price
- KCHV N/A
- RIGL $36.40
- AVG Volume (30 Days)
- KCHV 59.1K
- RIGL 182.1K
- Earning Date
- KCHV 01-01-0001
- RIGL 08-05-2025
- Dividend Yield
- KCHV N/A
- RIGL N/A
- EPS Growth
- KCHV N/A
- RIGL N/A
- EPS
- KCHV N/A
- RIGL 2.08
- Revenue
- KCHV N/A
- RIGL $203,077,000.00
- Revenue This Year
- KCHV N/A
- RIGL $14.41
- Revenue Next Year
- KCHV N/A
- RIGL $15.97
- P/E Ratio
- KCHV N/A
- RIGL $10.11
- Revenue Growth
- KCHV N/A
- RIGL 70.16
- 52 Week Low
- KCHV $9.99
- RIGL $8.61
- 52 Week High
- KCHV $10.24
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- KCHV N/A
- RIGL 66.30
- Support Level
- KCHV N/A
- RIGL $19.51
- Resistance Level
- KCHV N/A
- RIGL $21.41
- Average True Range (ATR)
- KCHV 0.00
- RIGL 0.88
- MACD
- KCHV 0.00
- RIGL 0.24
- Stochastic Oscillator
- KCHV 0.00
- RIGL 96.45
About KCHV KOCHAV DEFENSE ACQUISITION CORP.
Kochav Defense Acquisition Corp is a blank check company.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.